Hulio (Adalimumab-fkjp) for Psoriasis

Overview
Hulio is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with moderate to severe plaque psoriasis and active psoriatic arthritis. Hulio is also referred to by its drug name, adalimumab-fkjp.

Hulio is a member of a class of drugs called tumor necrosis factor (TNF) blockers. Hulio is believed to work by blocking the activity of TNF, a substance that can cause inflammation and immune system diseases. Hulio is biologically similar to the FDA-approved drug Humira (adalimumab).

How do I take it?
Prescribing information states that Hulio is administered every other week as a subcutaneous injection.

Hulio comes in the form of a single-dose prefilled pen and single-dose prefilled plastic syringe.

Side effects
The FDA-approved label for Hulio lists common side effects including upper respiratory infections, headache, rash, and injection site reactions like redness, swelling, itching, and bruising.

Rare but serious side effects listed for Hulio include serious infections, cancer, severe allergic reaction, reactivation of a hepatitis B virus infection, heart failure, lupus-like syndrome, and demyelinating disease (such as multiple sclerosis or Guillain-Barre syndrome).

For more details about this treatment, visit:

Hulio — RxList
https://www.rxlist.com/hulio-drug.htm

Hulio — European Medicines agency
https://www.ema.europa.eu/en/medicines/human/EP...